Acadia Pharma (ACAD) reported Q2 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $134.6 million versus the consensus estimate...
Pre-Open Stock Movers: Convey Health Solutions Holdings, Inc. (CNVY) 139% HIGHER; entered into a definitive merger agreement pursuant to which TPG Capital, the private equity...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The Company has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The Company also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).
|Average||23.38 (+29.50% Upside)|
|No. of Analysts||16|